Porto

• Pharmacokinetics and the Effect of Food on the Pharmacokinetics of TW102 in Healthy Subjects. Ended
  2024-510936-31-00 3 2024-10-01 No medical condition.
• Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended
  2024-511647-25-00 2 2024-09-24 No medical condition.
• Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended
  2024-512908-19-00 2 2024-09-09 No medical condition.
• Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (Hig … Ended
  2024-514298-23-00 3 2024-09-02 No medical condicion.
• Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers. Ended
  2023-508439-30-00 3 2024-08-21 Multiple Sclerosis
• Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL … Ended
  2024-513753-75-00 2 2024-08-12 No medical condition.
• Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions. Ended
  2024-514448-10-00 2 2024-08-09 No medical condition.
• Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended
  2024-513752-15-00 2 2024-08-01 No medical condition.
• Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended
  2024-513751-32-00 2 2024-07-24 No medical condition.
• Bioequivalence of Vortioxetine 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended
  2023-509422-21-00 2 2024-07-17 No medical condition.
• Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjects Ended
  2023-504901-34-00 2 2024-07-15 No medical condition.
• Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended
  2024-512910-16-00 2 2024-07-03 No medical condition.
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditio … Ended
  2024-512853-26-00 2 2024-06-27 No medical condition
• Comparative Pharmacokinetic of S221237 Tablets in Healthy Participants Under Fed Conditions Ended
  2024-511270-72-00 3 2024-06-13 No medical condition
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions Ended
  2024-512857-25-00 2 2024-05-21 No medical condition.
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2023-506557-38-00 5 2024-05-16 Dermatitis atopic
• Bioequivalence of Vortioxetine 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended
  2023-509419-10-00 2 2024-05-09 No medical condition
• Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditions Ended
  2023-509808-15-00 2 2024-04-29 No medical condition.
• Bioequivalence of Progesterone Vaginal Insert 100 mg in Healthy Pre-Menopausal, Nonpregnant Female Subjects. Ended
  2022-502614-82-00 2 2024-04-18 No medical condition.
• A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arteri … Ended
  2022-502378-17-00 4 2024-03-20 Pulmonary Arterial Hypertension
• Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fed Conditions Ended
  2023-504259-29-00 2 2024-03-18 No medical condition
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended
  2022-502713-29-00 5 2024-03-01 Dyskinesia due to cerebral palsy (DCP)

Showing 433–456 of 548 trials